Nasopharyngeal Pneumococcal Serotypes Before and After Mass Azithromycin Distributions for Trachoma | Zendy

Jeremy D. Keenan | Zendy; Ida Sahlu | Zendy; Lesley McGee | Zendy; Vicky Cevallos | Zendy; Jorge E. Vidal | Zendy; Sopio Chochua | Zendy; Paulina A. Hawkins | Zendy; Teshome Gebre | Zendy; Zerihun Tadesse | Zendy; Paul M. Emerson | Zendy; Bruce D. Gaynor | Zendy; Thomas M. Lietman | Zendy; Keith P. Klugman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nasopharyngeal Pneumococcal Serotypes Before and After Mass Azithromycin Distributions for Trachoma

Author(s) -

Jeremy D. Keenan,

Ida Sahlu,

Lesley McGee,

Vicky Cevallos,

Jorge E. Vidal,

Sopio Chochua,

Paulina A. Hawkins,

Teshome Gebre,

Zerihun Tadesse,

Paul M. Emerson,

Bruce D. Gaynor,

Thomas M. Lietman,

Keith P. Klugman

Publication year - 2015

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piu143

Subject(s) - azithromycin , trachoma , medicine , streptococcus pneumoniae , serotype , population , microbiology and biotechnology , virology , antibiotics , environmental health , biology , pathology

Twenty-four Ethiopian communities were randomized to receive either (1) quarterly mass azithromycin distributions for trachoma for 1 year or (2) delayed treatment. Nasopharyngeal swabs collected from separate cross-sectional population-based samples of children were processed for Streptococcus pneumoniae Mass azithromycin did not significantly alter the pneumococcal serotype distribution, and hence it would not be expected to alter vaccine coverage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research